Catalyst Pharmaceuticals Inc CPRX

Healthcare Biotechnology

Catalyst Pharmaceuticals, Inc. is a commercial-stage biopharmaceutical company. The Company is focused on developing and commercializing first-in-class medicines that address rare and difficult to treat diseases. Its flagship commercial product is FIRDAPSE (amifampridine) tablets 10 milligrams (mg), approved for the treatment of Lambert-Eaton Myasthenic Syndrome (LEMS) for adults and for children ages six to seventeen. The Company is also marketing FYCOMPA (perampanel) CIII as a prescription medication used alone or with other medicines to treat focal onset seizures with or without secondarily generalized seizures in people with epilepsy aged four and older and with other medicines to treat primary generalized tonic-clonic seizures in people with epilepsy aged 12 and older. Its portfolio also includes AGAMREE (vamorolone) an oral suspension 40 mg/ml for the treatment of Duchenne Muscular Dystrophy (DMD). The vamorolone is a corticosteroid treatment for patients suffering from DMD.

NDAQ:CPRX - Post by User

Catalyst Pharmaceuticals Inc

<< Previous

Bullboard Posts

Post by whytestockson Aug 20, 2024 4:00pm

36 Views

Post# 36188599

Catalyst Pharmaceuticals to Participate in Upcoming Investor

Just In: $CPRX Catalyst Pharmaceuticals to Participate in Upcoming Investor ConferencesCORAL GABLES, Fla., Aug. 20, 2024 (GLOBE NEWSWIRE) -- Catalyst Pharmaceuticals, Inc. ("Catalyst" or "Company") (Nasdaq: CPRX), a commercial-stage biopharmaceutical company focused on in-licensing, developing, and commercializing novel medicines for patients living with rare and difficult-to-treat...CPRX - Catalyst Pharmaceuticals to Participate in Upcoming Investor Conferences

<< Previous

Bullboard Posts

Here are three global stocks you should watch